GlassScriptPhysician profile
Adam Lish
NPI 1083711766
$2,612.78
in general payments reported to CMS, 2019-2025
20 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $32.62 · 2021: $310 · 2022: $374 · 2023: $606 · 2024: $342 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.50 | 2023-2025 | |
| Alcon Vision LLC | $348.95 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Biotissue Holdings INC. | $199.06 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $192.63 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| New World Medical,INC. | $188.28 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $184.53 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $148.46 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
| Genzyme Corporation | $99.70 | 2022 | |
| Allergan, INC. | $98.38 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.98 | 2019-2021 | |
| Glaukos Corporation | $81.76 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Thea Pharma INC. | $60.12 | 2024-2025 | Iyuzeh |
| Dompe US, INC. | $52.07 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $28.15 | 2022 | |
| Astellas Pharma US INC | $21.39 | 2025 | Izervay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $19.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.44 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.00 | 2019 | |
| Ocular Therapeutix, INC. | $14.12 | 2023 | Dextenza |
| Iridex Corporation | $8.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Lish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.